Published in Clin Pharmacokinet on January 01, 2008
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation (2015) 1.66
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol (2012) 1.53
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
Update on anti-coagulation in atrial fibrillation. QJM (2011) 1.28
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol (2013) 1.24
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum (2009) 1.14
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J (2014) 1.12
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol (2013) 1.11
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol (2011) 1.06
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol (2013) 1.03
Direct thrombin inhibitors. Br J Clin Pharmacol (2011) 1.01
2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg (2014) 0.99
Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol (2012) 0.97
Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens (2012) 0.96
Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos (2013) 0.92
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol (2013) 0.91
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One (2012) 0.90
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89
New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J (2013) 0.88
Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol (2011) 0.87
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr (2012) 0.86
Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors. PLoS One (2012) 0.86
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack. Can J Hosp Pharm (2015) 0.84
Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol (2013) 0.83
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomedicine (2011) 0.83
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
Management of postoperative atrial fibrillation. J Anesth (2012) 0.82
Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney Res Clin Pract (2014) 0.82
Beyond warfarin: The advent of new oral anticoagulants. Indian J Radiol Imaging (2016) 0.82
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract (2013) 0.81
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vasc Health Risk Manag (2013) 0.81
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. Case Rep Med (2013) 0.80
Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs (2013) 0.80
New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T (2011) 0.80
Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther (2016) 0.79
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits (2014) 0.79
New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis (2013) 0.78
Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol (2011) 0.78
Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic Clin Pharmacol Toxicol (2016) 0.78
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol (2014) 0.78
Oral anticoagulant-associated intracerebral hemorrhage. J Neurol (2011) 0.77
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol (2015) 0.77
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag (2014) 0.77
Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Mol Pharmacol (2015) 0.77
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
Promise and challenges of anticoagulation with dabigatran. Clin Kidney J (2012) 0.76
Advances in the diagnosis and treatment of acute pulmonary embolism. F1000 Med Rep (2012) 0.76
PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. Oncogene (2015) 0.76
Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects. Clin Drug Investig (2013) 0.76
Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. J Thorac Dis (2015) 0.76
Enhanced elimination of dabigatran through extracorporeal methods. J Med Toxicol (2015) 0.76
Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy (2015) 0.76
Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. J Am Heart Assoc (2015) 0.76
Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P T (2011) 0.75
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Am J Cardiovasc Drugs (2016) 0.75
Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol (2017) 0.75
Case report: dabigatran-associated gynecologic bleeding. Hosp Pharm (2013) 0.75
New anticoagulants in atrial fibrillation: an update for clinicians. Ther Adv Chronic Dis (2012) 0.75
Antithrombotic therapy in cardiac embolism. Curr Cardiol Rev (2010) 0.75
Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery. Case Rep Crit Care (2016) 0.75
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med (2017) 0.75
Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation. J Arrhythm (2014) 0.75
The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. Sci Rep (2016) 0.75
Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. CADTH Technol Overv (2010) 0.75
New oral anticoagulants for stroke prevention in atrial fibrillation: more choices bring more challenges. Hosp Pharm (2013) 0.75
Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atheroscler (2014) 0.75
New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis (2010) 0.75
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J (2015) 0.75
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ (2016) 0.75
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Ther Clin Risk Manag (2012) 0.75
Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovasc Diagn Ther (2014) 0.75
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ (2017) 0.75
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Des Devel Ther (2015) 0.75
Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate. Korean Circ J (2015) 0.75
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2017) 0.75
Dabigatran approaching the realm of heparin-induced thrombocytopenia. Blood Res (2016) 0.75
Structure-guided residence time optimization of a dabigatran reversal agent. MAbs (2015) 0.75
The Reversal of Direct Oral Anticoagulants in Animal Models. Shock (2017) 0.75
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. Drug Saf (2017) 0.75
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. Clin Nephrol Case Stud (2014) 0.75
Dabigatran-Induced Massive Spontaneous Hemothorax. Drug Saf Case Rep (2017) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75